Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-690, 550+ midazolam; midazolam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | - |
| Treatment Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| midazolam; CP-690,550 + midazolam | DRUG | Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID |
| CP-690,550 + midazolam; midazolam | DRUG | Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone |
Inclusion Criteria: * Healthy male and/or female (non-child bearing potential) subjects Exclusion Criteria: * Clinically significant infections within the past 3 months * History of previously untreated infection with Mycobacterium tuberculosis * Positive screening test for hepatitis B surface an...
CP 690,550 is an investigational small molecule being studied for multiple conditions, including renal impairment, Crohn's disease, hepatic insufficiency, dry eye syndromes, rheumatoid arthritis, and psoriasis. It is developed by Pfizer, Inc. (NYSE: PFE) and is currently in Phase 3 clinical development.
CP 690,550 is a small molecule immunology therapeutic. Its specific molecular target is not disclosed in the available information. It is being investigated for its potential role in treating autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease.
CP 690,550 is developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical trials for various indications, including psoriasis and rheumatoid arthritis.
CP 690,550 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Pfizer, Inc. is conducting clinical trials to evaluate its safety and efficacy for conditions such as psoriasis and other inflammatory diseases.
CP 690,550 has been studied in several clinical trials, including NCT00678210, a Phase 2 study in moderate to severe chronic plaque psoriasis, and NCT01519089, a Phase 3 long-term study in patients with moderate to severe plaque psoriasis and/or psoriatic arthritis. All trials are completed.
CP 690,550 is an alternative name for tofacitinib, a small molecule developed by Pfizer, Inc. It is being studied for various indications, including rheumatoid arthritis, psoriasis, and Crohn's disease. The drug is currently in Phase 3 clinical development.